China Biologic Products, Inc. (CBPO) - NASDAQ
  • Tue, Mar. 1, 6:01 PM
    • China Biologic (CBPO +3.2%) is announcing a secondary offering of 3.5M shares -- amounting to about $411.7M at its current price.
    • The company, a plasma-based biopharmaceutical with a market cap of nearly $3.1B, isn't selling any shares in the deal and won't receive any proceeds. Warburg Pincus and affiliates will sell the shares.
    • The number of shares to be sold amounts to about 13.2% of outstanding stock, and common stock outstanding won't change as a result. The offering's expected to close next Monday.
    • After hours: CBPO flat.
    | Tue, Mar. 1, 6:01 PM
  • Jun. 26, 2015, 5:37 PM
    | Jun. 26, 2015, 5:37 PM | 16 Comments
  • Jun. 8, 2015, 12:49 PM
    | Jun. 8, 2015, 12:49 PM | 26 Comments
  • Jul. 8, 2014, 12:46 PM
    | Jul. 8, 2014, 12:46 PM
  • Jun. 18, 2014, 12:45 PM
    | Jun. 18, 2014, 12:45 PM | 5 Comments
  • Feb. 19, 2014, 12:45 PM
    | Feb. 19, 2014, 12:45 PM | 1 Comment
  • Jun. 7, 2013, 12:45 PM
    Midday top 10 gainers: OSH +23%. WSBF +19%. OPTT +17%. CSFS +14%. BDBD +13%. JKS +11%. ROSG +11%. THO +10%. ECTY +10%. KFS +9%.
    Midday top 10 Losers: FSGI -56%. TIVO -17%. USM -17%. IRM -16%. ZQK -12%. JRCC -11%. LQDT -11%. AFFY -10%. CBPO -10%. TRUE -8%.
    | Jun. 7, 2013, 12:45 PM
  • Jan. 2, 2013, 2:51 PM

    China Biologic Products (CBPO -4.6%) slips after announcing earlier today that construction of a new production facility at its Guizhou Taibang subsidiary could be delayed due to slower-than-expected government approval of land use rights. The Company says it's working closely with local authorities to secure approval as soon as possible and will provide an update as soon as possible. CBPO had planned to commence work on the project in late 2012, with completion by mid-2014.

    | Jan. 2, 2013, 2:51 PM
  • Jul. 15, 2011, 4:04 PM

    China Biologic Products (CBPO -6.5%) takes a hit today after receiving notification from the Guizhou Provincial Health Department that the government has suspended the company's blood collection activities in the province. The suspension affects four of six collection sites it runs, and the impact upon current business operations could be significant.

    | Jul. 15, 2011, 4:04 PM
Company Description
China Biologic Products, Inc. is the non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. Through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and its equity investment in Xi'an... More
Sector: Healthcare
Industry: Biotechnology
Country: China